Synthesis, Biological Evaluation and Molecular Docking of Novel Phenylpyrimidine Derivatives as Potential Anticancer Agents

Abstract

Based on our previous researches, a novel phenylpyrimidine pharmacophore model was proposed and fifteen derivatives were synthesized and characterized by means of spectroscopy methods. The inhibitory effects of them were screened against HeLa cell line by virtue of MTT assay in vitro. The results indicate some of the phenyl-pyrimidine derivatives exhibit potent biological activities. Among them, compounds 6g and 6h exhibit the best activity at half maximal inhibitory concentrations of 1.5 and 2.8 μmol/L, respectively. These compounds also exhibit good activities against HepG2 cell line and MCF-7 cell line. FLT-3 kinase was screened as the most potent molecular target. Computational docking between compound 6g and FLT-3 was carried out to interpret the binding mode. The results show phenylpyrimidine derivatives have effective antitumor activities, which provides a base for further research of them as antitumor agents.

Keywords

Phenylpyrimidine / Anticancer activity / Molecular docking

References

[1] Siegel R. L., Miller K. D., Jemal A. Cancer statistics, 2016, 66(1): 7.

[2] Vineis P., Christopher P. W. Lancet, 2014, 383(9916): 549.

[3] Creixell M., Peppa N. A. Nano Today, 2012, 7(4): 367.

[4] Takara K., Sakaeda T., Okumura K. Curr. Pharm. Design, 2006, 12(3): 273.

[5] Raez L. E., Lilenbaum R. Clin. Adv. Hemato. Oncol., 2004, 2(3): 173.

[6] Santin M. T., Rainaldi G., Indovina P. L. Crit. Rev. Oncol. Hemat., 2000, 36(2): 75.

[7] Marsoni S., Damia G. Ann. Oncol., 2004, 15: 229.

[8] Cummings J., Ward T. H., Ranson M., Dive C. Biochimica et Biophysica Acta—Rev. Cancer, 2004, 1705(1): 53.

[9] Xie H. Z., Li L. L., Ren J. X., Zou J., Yang L., Wei Y. Q., Yang S. Y. Bioorg. Med. Chem. L., 2009, 19(7): 1944.

[10] Hsu Y. C., Weng H. C., Lin S. R., Chien Y. W. J. Agr. Food Chem., 2007, 55(20): 8213.

[11] Wang L., Zheng G. J., Ji Q., Chen B., Gong L. L., Gao C. M., Du Z. J., Zhang X. M. Chem. J. Chinese Universities, 2017, 38(9): 1590.

[12] Bai X. F., Ma X., Xie X. X., Shao M. S., Guo N. N., Yan N., Yao L. Chem. J. Chinese Universities, 2017, 38(1): 47.

[13] Yang H. L., Xu G. X., Pei Y. Z. Chem. Res. Chin. Universities, 2017, 33(1): 61.

[14] Yang H. L., Xu G. X., Bao M. Y., Zhang D. P., Li Z. W., Pei Y. Z. Chem. J. Chinese Universities, 2015, 35(12): 2584.

[15] Zorn J. A., Wang Q., Fujimura E., Barros T., Kuriyan J. PLoS One, 2015, 10(4): e0121177.

[16] Hussain M., Hung N. T., Khera R. A., Malik I., Zinad D. S., Langer P. Adv. Synth. Catal., 2010, 352(9): 1429.

[17] Liu J., Fitzgerald A. E., Mani N. S. J. Org. Chem., 2008, 73(7): 2951.

[18] Anderson S. C., Handy S. T. Synthesis., 2010, 16: 2721.

[19] Zhu L., Duquette J., Zhang M. J. Org. Chem., 2003, 68(9): 3729.

[20] Zhang Y., Gao J., Li W., Lee H., Lu B. Z., Senanayake C. H. J. Org. Chem., 2011, 76(15): 6394.

[21] Gerebtzoff G., Li-Blatte X., Fischer H., Frentzel A., Seelig A. Chem. Bio. Chem., 2004, 5(5): 676.

[22] Gentry C. L., Egleton R. D., Gillespie T., Abbruscato T. J., Bechows-ki H. B., Hruby V. J., Davis T. P. Peptides, 1999, 20(10): 1229.

[23] Metrangolo P., Neukirch H., Pilati T., Resnati G. Acc. Chem. Res., 2005, 38(5): 386.

[24] Metrangolo P., Resnati G. Chem. Eur. J., 2001, 7(12): 2511.

[25] Auffinger P., Hays F. A., Westhof E., Ho P. S. Proc. Natl. Acad. Sci. USA, 2004, 101(48): 16789.

[26] Rogez-Florent T., Meignan S., Foulon C., Six P., Gros A., Bal-Mahieu C., Supuran C. T., Scozzafava A., Frédérick R., Masereel B., Depreux P., Lansiaux A., Goossens J. F., Gluszok S., Goossens L. Bioorg. Med. Chem., 2013, 21(6): 1451.

[27] Hartshorn M. J., Murray C. W., Cleasby A., Frederickson M., Tickle I. J., Jhoti H. J. Med. Chem., 2005, 48(2): 403.

[28] Badrinarayan P., Sastry G. N. J. Chem. Inf. Model., 2011, 51(1): 115.